Researchers from Stanford have developed a novel topical pharmaceutical composition comprising of a chemical inhibitor encapsulated in nanomicelles for the treatment of vision loss associated with acute optic neuropathies.
Stanford researchers have repurposed two existing drugs and created a combined nanoparticle formulation that provides both intraocular pressure management and neuroprotection for glaucoma therapy.
To manage the development and progression of glaucoma, researchers at Stanford University have developed a biocompatible suprachoroidal spacer implant.